Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss is a research paper published in Pharmaceuticals (2024). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health NIDCD
Grant: 1R01DC018850
National Institutes of Health NIDCD
Grant: 1F32DC020102
NIGMS NIH HHS
Grant: P20 GM139762
American Hearing Research Foundation
Grant: 2020 to T. Teitz
NCRR NIH HHS
Grant: G20 RR024001
NIDCD NIH HHS
Grant: F32 DC020102
NIH HHS
Grant: 1R01DC018850-24A4
NIDCD NIH HHS
Grant: R01 DC018850
NIGMS NIH HHS
Grant: P20 GM103427
NCRR NIH HHS
Grant: P20 RR016469
NIH HHS
Grant: 1F32DC020102-23A2
National Institutes of Health
Grant: 5R01DC018850-06
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss
National Institutes of Health
Grant: 1P20GM139762-01
Translational Hearing Center
National Institutes of Health
Grant: 1F32DC020102-01
Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing Loss
National Institutes of Health
Grant: 1G20RR024001-01
Replacing an Animal Resource Facility Cage Washer.
FWCI
0.99
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals